Long Ideas - PropThink’s readers will be aware of our bullish outlook on Sarepta Therapeutics (SRPT), and Thursday’s commentary that a NDA filing may still be months away … Continue Reading
Read nowLong Ideas - Shares of Keryx Biopharmaceuticals (KERX) continue to trade within a tight range, but with several catalyzing events approaching, we believe the stock is ready to … Continue Reading
Read nowLong Ideas - It doesn’t get much better than this, and Synergy Pharmaceuticals (SGYP) remains a favorite PropThink idea. The company’s lead drug candidate, plecanatide, has demonstrated strong … Continue Reading
Read nowLong Ideas - Things are looking up for Cubist Pharmaceuticals (CBST). As we speculated last week, a key piece of Cubist’s ongoing litigation with Hospira has gone in … Continue Reading
Read nowLong Ideas - This Tuesday, Synergy Pharmaceuticals (SGYP) will release the full data set from its recently completed trial for lead candidate plecanatide at the annual Digestive Disease … Continue Reading
Read nowLong Ideas - With a capital raise recently out of the way and a pivotal trial enrolling towards a regulatory filing in the U.S., Sunshine Heart’s (SSH) $60M … Continue Reading
Read nowLong Ideas - Shares of Cubist Pharmaceuticals (CBST) have not significantly participated in the market rally, and relative to biotech peers, CBST has lagged on performance as well; … Continue Reading
Read now